{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:35Z","timestamp":1790965115285,"version":"4.1.0"},"reference-count":82,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"published-print":{"date-parts":[[2013,8,1]]},"DOI":"10.1136\/jnnp-2012-302310","type":"journal-article","created":{"date-parts":[[2012,11,11]],"date-time":"2012-11-11T02:44:19Z","timestamp":1352601859000},"page":"922-930","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":145,"title":["Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders"],"prefix":"10.1136","volume":"84","author":[{"given":"A.","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McKeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. K.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Elsone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,11,10]]},"reference":[{"key":"key-10.1136\/jnnp-2012-302310-1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.56.4.507","article-title":"MS and neuromyelitis optica in Martinique (French West Indies)","volume":"56","author":"Cabre","year":"2001","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-Gomez","year":"2009","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1212\/WNL.0b013e31822c61b1","article-title":"AQP4 antibody-positive Thai cases: clinical features and diagnostic problems","volume":"77","author":"Siritho","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: a multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2012-302310-8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation."},{"key":"key-10.1136\/jnnp-2012-302310-9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/WNL.0b013e3181ea9f15","article-title":"Familial neuromyelitis optica","volume":"75","author":"Matiello","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1212\/WNL.0b013e31822f045b","article-title":"Genetic analysis of aquaporin-4 in neuromyelitis optica","volume":"77","author":"Matiello","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-12","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ana.22121","article-title":"Intractable vomiting as the initial presentation of neuromyelitis optica","volume":"68","author":"Apiwattanakul","year":"2010","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-15","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1212\/WNL.0b013e3182343377","article-title":"Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica","volume":"77","author":"Iorio","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","article-title":"Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study","volume":"77","author":"Kanamori","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.0b013e31824f8069","article-title":"Clinical spectrum of CNS aquaporin-4 autoimmunity","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-19","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/jnnp-2012-302310-20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jnnp.2008.168070","article-title":"Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica","volume":"81","author":"de Seze","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2012-302310-22","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2012-302310-23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"key-10.1136\/jnnp-2012-302310-24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997","article-title":"Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain","volume":"17","author":"Nielsen","year":"1997","journal-title":"J Neurosci"},{"key":"key-10.1136\/jnnp-2012-302310-25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archneurol.2009.178","article-title":"Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays","volume":"66","author":"McKeon","year":"2009","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-26","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WCO.0b013e3283533a3f","article-title":"Neuromyelitis optica: not a multiple sclerosis variant","volume":"25","author":"Barnett","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.210.307","article-title":"Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica","volume":"210","author":"Takahashi","year":"2006","journal-title":"Tohoku J Exp Med"},{"key":"key-10.1136\/jnnp-2012-302310-30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1515\/CCLM.2010.127","article-title":"Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica","volume":"48","author":"Jarius","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"key-10.1136\/jnnp-2012-302310-32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.21197","article-title":"Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica","volume":"39","author":"McKeon","year":"2009","journal-title":"Muscle Nerve"},{"key":"key-10.1136\/jnnp-2012-302310-35","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-36","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2012-302310-37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/1352458507084107","article-title":"Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome","volume":"14","author":"Mehta","year":"2008","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2012-302310-38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/jnnp.2007.143263","article-title":"Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4","volume":"79","author":"Jarius","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2012-302310-39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archneurol.2011.200","article-title":"Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle?","volume":"68","author":"Vaknin-Dembinsky","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-40","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.neuroscience.2004.06.088","article-title":"New insights into water transport and edema in the central nervous system from phenotype analysis of aquaporin-4 null mice","volume":"129","author":"Manley","year":"2004","journal-title":"Neuroscience"},{"key":"key-10.1136\/jnnp-2012-302310-41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-386043-9.00001-3","article-title":"Structure and functions of aquaporin-4-based orthogonal arrays of particles","volume":"287","author":"Wolburg","year":"2011","journal-title":"Int Rev Cell Mol Biol"},{"key":"key-10.1136\/jnnp-2012-302310-42","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J Exp Med"},{"key":"key-10.1136\/jnnp-2012-302310-43","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-44","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment","volume":"181","author":"Vincent","year":"2008","journal-title":"J Immunol"},{"key":"key-10.1136\/jnnp-2012-302310-45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/jnnp-2012-302310-46","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/jnnp-2012-302310-47","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2012-302310-48","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2012-302310-49","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2012-302310-50","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin\u20134 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","article-title":"Neuromyelitis optica: Passive transfer to rats by human immunoglobulin","volume":"386","author":"Kinoshita","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.1136\/jnnp-2012-302310-53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2012-302310-54","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-55","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Magana","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","article-title":"Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination","volume":"252","author":"Warabi","year":"2007","journal-title":"J Neurol Sc."},{"key":"key-10.1136\/jnnp-2012-302310-57","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-58","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.it.2011.03.008","article-title":"Interferon-beta exacerbates Th17-mediated inflammatory disease","volume":"32","author":"Axtell","year":"2011","journal-title":"Trends Immunol"},{"key":"key-10.1136\/jnnp-2012-302310-59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1756285608093978","article-title":"Treatment of neuromyelitis optica: current debate","volume":"1","author":"Okamoto","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"key":"key-10.1136\/jnnp-2012-302310-60","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-61","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2012-302310-62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2012-302310-63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2012-302310-64","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-65","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-67","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neuro"},{"key":"key-10.1136\/jnnp-2012-302310-68","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-69","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-70","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2012-302310-71","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neurmyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2012-302310-72","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2\u2005years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-74","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-75","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7224\/1537-2073-2.4.43","article-title":"Treatment of Devic's Disease With Methotrexate and Prednisone","volume":"2","author":"Minagar","year":"2000","journal-title":"Int J MS Care (on-line)"},{"key":"key-10.1136\/jnnp-2012-302310-76","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/j.1468-1331.2007.01807.x","article-title":"Relapsing neuromyelitis optica responsive to glatiramer acetate treatment","volume":"14","author":"Gartzen","year":"2007","journal-title":"Eur J Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-003-0979-2","article-title":"A case of relapsing neuromyelitis optica treated with glatiramer acetate","volume":"250","author":"Bergamaschi","year":"2003","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-78","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1744-9987.2009.00780.x","article-title":"Intermittent plasmapheresis prevents recurrence in neuromyelitis optica","volume":"13","author":"Miyamoto","year":"2009","journal-title":"Ther Apher Dial"},{"key":"key-10.1136\/jnnp-2012-302310-79","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archneurol.2011.38","article-title":"Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica","volume":"68","author":"Matiello","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-80","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-81","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archneurol.2011.127","article-title":"A benign form of neuromyelitis optica: does it exist?","volume":"68","author":"Collongues","year":"2011","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2012-302310-82","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2012-302310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:47:30Z","timestamp":1601056050000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2012-302310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,10]]},"references-count":82,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,7,8]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1136\/jnnp-2012-302310","relation":{},"ISSN":["0022-3050"],"issn-type":[{"value":"0022-3050","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11,10]]}}}